Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 2/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065985 | 0.90 | HINT1 (0.59) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL7101380 | 0.88 | HPGD (0.60) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL16359926 | 0.87 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL20444711 | 0.87 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL22883381 | 0.87 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL23679991 | 0.87 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL1639395 | 0.87 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL23425431 | 0.87 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL1374872 | 0.87 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL17976623 | 0.87 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223173-B1 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | EP | claimed |
| EP-0651759-B1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS INC (US) | 2003-12-10 | — | — | EP | claimed |
| EP-1223173-A2 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | claimed |
| US-5856466-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | claimed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | claimed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | claimed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | claimed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | claimed |
| JP-10087689-A | — | — | None | — | — | JP | disclosed |
| US-20260043027-A1 | LINKER, COMPOUND INCLUDING LINKER, METHOD OF PREPARING COMPOUND, USE OF LINKER, AND METHOD OF DELIVERING OLIGONUCLEOTIDES THROUGH LINKER | SYNERK BIOTECH LTD (HK) | 2026-02-12 | — | — | US | disclosed |
| CN-107532162-A | Compositions and methods for editing nucleic acids in cells using oligonucleotides | 托德·M·伍尔夫 | 2018-01-02 | — | — | CN | disclosed |
| US-20060074035-A1 | Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections | VALEANT RESEARCH & DEVELOPMENT | 2006-04-06 | — | — | US | disclosed |
| EP-1223173-B1 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-0651759-B1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS INC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-5856466-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| JP-H1087689-A | PRODUCTION OF 2'-O-ALKYLATED GUANOSINE 3'-O-PHOSPHOROAMIDITE | ISIS PHARMACEUT INC | 1998-04-07 | — | — | JP | disclosed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260043027-A1 | LINKER, COMPOUND INCLUDING LINKER, METHOD OF PREPARING COMPOUND, USE OF LINKER, AND METHOD OF DELIVERING OLIGONUCLEOTIDES THROUGH LINKER | SSU72, NSUN2, RNMT | HINT1 4616/4885HPGD 4804/4885NT5E 1595/4885 |
| US-20060074035-A1 | Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections | POLRMT, ADAR, POLM | HINT1 244/4885HPGD 1069/4885NT5E 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.